Mayne Pharma Group (MYX) H2 2024 earnings summary

Executive summary

• Achieved all key operating goals for FY24, including 112% revenue growth to $388.4m, positive direct contribution in all segments, return to positive underlying EBITDA, cost base optimization, break-even run rate for NEXTSTELLIS®, and positive operating cash generation.

• Gross margin expanded to 56.3%, with gross profit up 162% to $218.8m and underlying EBITDA improving by $118.2m to $22.9m.

• Net loss after tax reduced by 47% to $168.6m compared to the prior year.

• Significant operational improvements in Women's Health and Dermatology, with expanded product portfolios and refined US channel strategy.

• Positive free cash flow generated in the second half, first time in several years.

Financial highlights

• Revenue: $388.4m, up 112% year-over-year; gross profit up 162% to $218.8m; gross margin at 56.3%.

• Underlying EBITDA: $22.9m, a $118.2m improvement from FY23's loss.

• Direct contribution improved by $130.3m to $88.5m.

• Operating cash flow from continuing operations: $8.1m, up from a $51.5m outflow in FY23.

• Cash and marketable securities at June 30: $149.3m, down from $220.1m in FY23.

Outlook and guidance

• Expects continued growth in underlying EBITDA and revenue in FY25, with all segments projected to deliver positive direct contribution.

• Focus on maximizing profit potential in Women's Health, expanding Dermatology channel strategy, and completing facility modernization for International segment.

• Women's Health to focus on sales execution and targeted marketing to increase operating leverage.

• Dermatology to pursue capital-efficient, accretive business arrangements and leverage channel strategy.

• International segment to capitalize on operational improvements and investments.